Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

June 6th 2017

Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?

Surabhi Dangi-Garimella, PhD

A discussion at the 2017 American Society of Clinical Oncology Annual Meeting addressed the practical solutions to address the financial toxicity of cancer care and identified leads for future intervention studies aiming to prevent or reduce this burden.

June 6th 2017

Researchers Find Correlation Between Gut Microbiome and Immunotherapy Response in Melanoma

Laura Joszt, MA

Bacteria in the gut microbiome is associated with disease progression or delay in patients with metastatic melanoma who were treated with immunotherapy, according to a study presented at the 2017 American Society of Clinical Oncology Annual Meeting.

June 5th 2017

Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model

The collaboration between Innovative Oncology Business Solutions and the American Society of Clinical Oncology on the COME HOME Model should help give community oncology practices a path forward to be competitive, said Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.

June 5th 2017

Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk

Surabhi Dangi-Garimella, PhD

Updated results from the POLLUX and CASTOR trials, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that including daratumumab in standard-of-care regimens prolonged progression-free survival (PFS) and improved the depth of response, independent of the patients’ cytogenetic risk.

June 5th 2017

Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma

Craig Portell, MD, of the University of Virginia Health System, highlights some of the latest and most exciting treatments in non-Hodgkin's lymphoma, including CAR-T therapies and targeted therapies such as venetoclax.

June 4th 2017

Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer

Surabhi Dangi-Garimella, PhD

A phase 3, randomized, double-blind registration study in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar after switching studies.

June 4th 2017

Do We Have Adequate Surveillance in Cancer Survivor Care?

Surabhi Dangi-Garimella, PhD

A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology examined retrospective surveillance data in 3 different cancers: non-small cell lung cancer, head and neck cancer, and colorectal cancer.

June 4th 2017

Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success

As practices participating in the Oncology Care Model progress in their practice transformation they run into some challenges, such as how to properly analyze claims data, and see early successes, such as improved patient experience, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

June 3rd 2017

Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data

Surabhi Dangi-Garimella, PhD

One of the kickoff sessions on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, was a lively discussion on ensuring that the data used to inform patient care and create healthcare policies holds value.

June 3rd 2017

Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC

Surabhi Dangi-Garimella, PhD

A late afternoon extended education session on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, was a discussion on the state-of-the-art uses for immunotherapy in the management of non-small cell lung cancer (NSCLC).

June 3rd 2017

Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers

Checkpoint inhibitors have begun to revolutionize bladder cancer treatments, but the benefits in prostate cancer are a little less clear at this point, explained Daniel George, MD, of the Duke Cancer Insitute.

June 2nd 2017

Women Living in Isolated White Communities at High Risk of Later Breast Cancer Diagnosis

Christina Mattina

According to a recent study, women who live in a highly segregated white community are more likely to receive a late-stage diagnosis of breast cancer.

June 2nd 2017

What We're Reading: Taxing Employer Health Plans; Global Cancer Costs; Surviving an Overdose

AJMC Staff

June 1st 2017

ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation

Surabhi Dangi-Garimella, PhD

Analysis of data available within a national hospital-based registry showed that the diagnosis of stage I disease increased for female breast cancer, colorectal cancer, and lung cancer following implementation of the Affordable Care Act (ACA).

May 31st 2017

Bariatric Surgery Linked to Lower Risk of Female-Specific Cancers

Christina Mattina

A new study finds that bariatric surgery can have beneficial effects for women beyond just weight loss: it was also associated with lower risk of female-specific cancers, like breast or ovarian cancer.

May 31st 2017

HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults

Surabhi Dangi-Garimella, PhD

According to the study, to be presented at the 2017 American Society of Clinical Oncology Annual Meeting, vaccination resulted in an 88% overall reduction in vaccine-type infections and a 100% reduction among men, in the young adult population.

May 30th 2017

Ceritinib Approved as First Line for ALK-Positive Advanced NSCLC

Surabhi Dangi-Garimella, PhD

Patients with metastatic non-small cell lung cancer (NSCLC) who have a rearrangement in the anaplastic lymphoma kinase (ALK) gene now have a first-line option: ceritinib.

May 29th 2017

Physical Activity, Healthy Diet Improve Survival in Colorectal Cancer: Study at ASCO

Surabhi Dangi-Garimella, PhD

The findings are the results of a collaborative study conducted at various cancer institutions across the United States, which evaluated the impact of following the 2012 American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors.

May 26th 2017

This Week in Managed Care: May 26, 2017

This week, the top managed care news included the Congressional Budget Office's new score for the American Health Care Act; the White House released its fiscal year 2018 budget; and a cancer drug approval that is a first for the FDA.

May 26th 2017

Ahead of ASCO, Kite Pharma Announces Priority Review of Its CAR-T Treatment

Surabhi Dangi-Garimella, PhD

Based on the results of the phase 2 ZUMA-1 trial in patients with refractory non-Hodgkin lymphoma, Kite Pharma has submitted for, and received, a priority review for its chimeric antigen receptor (CAR)-T cell treatment, axicabtagene ciloleucel.

May 25th 2017

Physician-Patient Responsible for Ban on Power Morcellators, Dies

Surabhi Dangi-Garimella, PhD

Amy J. Reed, MD, died 4 years following her surgery that used a power morcellator to remove her uterus, resulting in the spread of a hidden cancer.

May 23rd 2017

A First: FDA Approves Pembrolizumab for Tissue-Agnostic Indication

Surabhi Dangi-Garimella, PhD

The drug is now indicated for adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors that lack suitable alternative treatments or that have progressed on treatment.

May 23rd 2017

Study Identifies Racial Disparity in Risk of Interval Colorectal Cancer

Surabhi Dangi-Garimella, PhD

A study published in the Annals of Internal Medicine reports that black Medicare enrollees are less likely to receive colonoscopy from more highly-rated physicians, which could increase their risk for interval colorectal cancer.

May 22nd 2017

Multigene Testing Can Inform Predisposition to Inherited Prostate Cancer

Surabhi Dangi-Garimella, PhD

Comprehensive genetic testing using multigene testing panels for prostate cancer can arm genetic counselors with the information they need to guide precision therapy, even in men with early stage disease but a strong family history of the disease.

May 22nd 2017

Report Outlines Burden of Rare Cancers, Including Poorer Survival Rates

Christina Mattina

Although each individual rare cancer affects a small percentage of patients, the collective group of 181 rare cancers is responsible for significant disease burden in the United States.

May 20th 2017

Dr Matthew Gubens Outlines Exciting Directions for Lung Cancer Immunotherapy Research

Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco, discussed the areas of lung immuno-oncology research where he anticipates significant advances will be made in coming years.

May 19th 2017

Study Identifies Patterns of Peer Pressure With Advanced Imaging in Breast Cancer

Surabhi Dangi-Garimella, PhD

A research study by scientists at Yale and Johns Hopkins has found that surgeons are influenced by their peers when it comes to the use of new imaging technologies.

May 18th 2017

Avalere and FasterCures Release Patient-Perspective Value Framework 1.0

Surabhi Dangi-Garimella, PhD

A year-long collaboration between a health consultancy and a think tank has resulted in the first draft of a framework that considers the value of healthcare services from the patient’s perspective.

May 18th 2017

FDA's Pazdur Outlines How Oncology Center of Excellence Will Promote Collaboration in AJMC®'s Evidence-Based Oncology

The National Cancer Moonshot initiative called for tearing down the silos that prevent researchers from sharing information. FDA’s Richard Pazdur, MD, is doing just that-through the new Oncology Center of Excellence. Pazdur shares how the center will work in a special issue of Evidence-Based Oncology, publication of The American Journal of Managed Care.®

May 17th 2017

FDA Oncology Center of Excellence Moves Forward on Coordinated Clinical Reviews, Integrated Approach to the Clinical Evaluation of Oncology Products

Richard Pazdur, MD

An overview of the FDA's Oncology Center of Excellence-a collaborative approach to the clinical approval process.

...

71 72 73 74 75 76 77 78 79

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions